Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2005 1
2007 2
2014 2
2017 1
2018 1
2019 1
2020 2
2021 2
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Results by year

Filters applied: . Clear all
Page 1
Deep morphea.
Bielsa I, Ariza A. Bielsa I, et al. Semin Cutan Med Surg. 2007 Jun;26(2):90-5. doi: 10.1016/j.sder.2007.02.005. Semin Cutan Med Surg. 2007. PMID: 17544960 Review.
Deep morphea encompasses a variety of clinical entities in which inflammation and sclerosis are found in the deep dermis, panniculus, fascia, or superficial muscle. Morphea profunda, eosinophilic fasciitis, and disabling pansclerotic morphea of children are included …
Deep morphea encompasses a variety of clinical entities in which inflammation and sclerosis are found in the deep dermis, panniculus, fascia …
Treatment in Juvenile Scleroderma.
Zulian F, Tirelli F. Zulian F, et al. Curr Rheumatol Rep. 2020 Jun 26;22(8):45. doi: 10.1007/s11926-020-00910-x. Curr Rheumatol Rep. 2020. PMID: 32591919 Review.
RECENT FINDINGS: According to the recent recommendations for Pediatric Rheumatology in Europe (SHARE), systemic treatment in localized scleroderma is needed when there is a risk for disability, such as in generalized or pansclerotic morphea and progressive linear sc …
RECENT FINDINGS: According to the recent recommendations for Pediatric Rheumatology in Europe (SHARE), systemic treatment in localized scler …
An Evaluation of the Performance of Current Morphea Subtype Classifications.
Prasad S, Zhu JL, Schollaert-Fitch K, Torok KS, Jacobe HT. Prasad S, et al. JAMA Dermatol. 2021 Apr 1;157(4):1-8. doi: 10.1001/jamadermatol.2020.5809. JAMA Dermatol. 2021. PMID: 33595618 Free PMC article.
With the use of the previously published Padua criteria, most patients were classified to have linear morphea (474 [50%]), followed by generalized morphea (244 [26%]), plaque morphea (141 [15%]), mixed morphea (38 [4%]), and pansclerotic morphea (3 [0.3%]). Overall, …
With the use of the previously published Padua criteria, most patients were classified to have linear morphea (474 [50%]), followed by gener …
Mycophenolate mofetil for methotrexate-resistant juvenile localized scleroderma.
Martini G, Saggioro L, Culpo R, Vittadello F, Meneghel A, Zulian F. Martini G, et al. Rheumatology (Oxford). 2021 Mar 2;60(3):1387-1391. doi: 10.1093/rheumatology/keaa392. Rheumatology (Oxford). 2021. PMID: 32978631 Free PMC article.
The most represented clinical subtypes in the MMF-group were pansclerotic morphea and mixed subtype (P = 0.008 and P = 0.029, respectively), and linear scleroderma of the face in the MTX-group (P = 0.048). ...
The most represented clinical subtypes in the MMF-group were pansclerotic morphea and mixed subtype (P = 0.008 and P = 0.029, …
Connective tissue nevus misdiagnosed as juvenile localized scleroderma.
Tirelli F, Giraudo C, Soliani M, Calabrese F, Martini G, Gisondi P, Meneghel A, Zulian F. Tirelli F, et al. Pediatr Rheumatol Online J. 2023 Oct 17;21(1):125. doi: 10.1186/s12969-023-00913-9. Pediatr Rheumatol Online J. 2023. PMID: 37848914 Free PMC article.
The indurated skin lesions were flat and resembled either circumscribed morphea or pansclerotic morphea. In 14 patients (82.4%) they were mainly localized at the lower limbs and in three (17.6%) at the upper limbs. ...
The indurated skin lesions were flat and resembled either circumscribed morphea or pansclerotic morphea. In 14 patients (82.4% …
Disabling pansclerotic morphea of childhood poses a high risk of chronic ulceration of the skin and squamous cell carcinoma.
Wollina U, Buslau M, Heinig B, Petrov I, Unger E, Kyriopoulou E, Koch A, Köstler E, Schönlebe J, Haroske G, Doede T, Pramatarov K. Wollina U, et al. Int J Low Extrem Wounds. 2007 Dec;6(4):291-8. doi: 10.1177/1534734607308731. Int J Low Extrem Wounds. 2007. PMID: 18048875 Review.
Disabling pansclerotic morphea of childhood (DPMC) is a rare and severe variant of scleroderma. ...
Disabling pansclerotic morphea of childhood (DPMC) is a rare and severe variant of scleroderma. ...
Evaluation of the Effectiveness and Tolerability of Mycophenolate Mofetil and Mycophenolic Acid for the Treatment of Morphea.
Arthur M, Fett NM, Latour E, Jacobe H, Kunzler E, Florez-Pollack S, Houser J, Sharma S, Prasad S, Femia A, Stern MJ, Pappas-Taffer LK, Gaffney R, Fernandez AP, Knabel D, Cardones AR, Leung N, Laumann A, Yu JM, Zhao J, Vleugels RA, Tkachenko E, Lo K. Arthur M, et al. JAMA Dermatol. 2020 May 1;156(5):521-528. doi: 10.1001/jamadermatol.2020.0035. JAMA Dermatol. 2020. PMID: 32236497 Free PMC article.
RESULTS: There were 61 female patients (79%) and 16 male patients (21%) in the study, with a median age at disease onset of 36 years (interquartile range, 16-53 years) and median diagnostic delay of 8 months (interquartile range, 4-14 months). Generalized morphea (37 [48%]), p …
RESULTS: There were 61 female patients (79%) and 16 male patients (21%) in the study, with a median age at disease onset of 36 years (interq …
Unilateral linear pansclerotic morphea affecting face and limbs.
Padmavathy L, Rao LL. Padmavathy L, et al. Indian J Dermatol Venereol Leprol. 2005 May-Jun;71(3):192-4. doi: 10.4103/0378-6323.16237. Indian J Dermatol Venereol Leprol. 2005. PMID: 16394411
Disabling pansclerotic morphea is a rare atrophying and sclerosing disorder of the subcutaneous tissue, muscle and bone. ...
Disabling pansclerotic morphea is a rare atrophying and sclerosing disorder of the subcutaneous tissue, muscle and bone. ...
Disabling pansclerotic morphea of childhood and hypogammaglobulinemia: a curious association.
Devidayal, Singh S, Kumar L, Radotra BD. Devidayal, et al. Rheumatol Int. 2002 Jan;21(4):158-60. doi: 10.1007/s00296-001-0150-2. Rheumatol Int. 2002. PMID: 11843172
Biopsy of the involved areas showed features consistent with pansclerotic morphea. Immunoglobulin estimation revealed hypogammaglobulinemia. This unique combination of pansclerotic morphea with hypogammaglobulinemia has not been reported before....
Biopsy of the involved areas showed features consistent with pansclerotic morphea. Immunoglobulin estimation revealed hypogamm …
Disease course and long-term outcome of juvenile localized scleroderma: Experience from a single pediatric rheumatology Centre and literature review.
Martini G, Fadanelli G, Agazzi A, Vittadello F, Meneghel A, Zulian F. Martini G, et al. Autoimmun Rev. 2018 Jul;17(7):727-734. doi: 10.1016/j.autrev.2018.02.004. Epub 2018 May 3. Autoimmun Rev. 2018. PMID: 29729451 Review.
The delay in start of systemic treatment was associated with longer disease activity and higher relapse rate. Patients with linear scleroderma (LS), pansclerotic morphea (PM) and mixed subtype (MS) presented more severe aesthetic and functional damage but did not di …
The delay in start of systemic treatment was associated with longer disease activity and higher relapse rate. Patients with linear scleroder …
14 results